nodes	percent_of_prediction	percent_of_DWPC	metapath
Olmesartan—SLCO1B3—Mycophenolate mofetil—psoriasis	0.175	0.249	CbGbCtD
Olmesartan—SLCO1B1—Mycophenolate mofetil—psoriasis	0.102	0.145	CbGbCtD
Olmesartan—ABCC2—Mycophenolate mofetil—psoriasis	0.0893	0.127	CbGbCtD
Olmesartan—SLCO1B1—Cyclosporine—psoriasis	0.077	0.11	CbGbCtD
Olmesartan—SLCO1B3—Methotrexate—psoriasis	0.07	0.0998	CbGbCtD
Olmesartan—ABCC2—Cyclosporine—psoriasis	0.0677	0.0965	CbGbCtD
Olmesartan—ABCC2—Dexamethasone—psoriasis	0.0446	0.0636	CbGbCtD
Olmesartan—SLCO1B1—Methotrexate—psoriasis	0.0408	0.0581	CbGbCtD
Olmesartan—ABCC2—Methotrexate—psoriasis	0.0358	0.0511	CbGbCtD
Olmesartan—Irbesartan—JUN—psoriasis	0.00368	0.583	CrCbGaD
Olmesartan—Telmisartan—PPARG—psoriasis	0.00178	0.282	CrCbGaD
Olmesartan—Losartan—ACE—psoriasis	0.000849	0.135	CrCbGaD
Olmesartan—AGTR1—Allograft Rejection—IL22—psoriasis	0.000721	0.151	CbGpPWpGaD
Olmesartan—AGTR1—ACE Inhibitor Pathway—REN—psoriasis	0.000616	0.129	CbGpPWpGaD
Olmesartan—AGTR1—ACE Inhibitor Pathway—ACE—psoriasis	0.000384	0.0806	CbGpPWpGaD
Olmesartan—ABCC2—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.000186	0.039	CbGpPWpGaD
Olmesartan—SLCO1B1—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.000175	0.0367	CbGpPWpGaD
Olmesartan—AGTR1—Allograft Rejection—HLA-C—psoriasis	0.000137	0.0286	CbGpPWpGaD
Olmesartan—AGTR1—Allograft Rejection—IL13—psoriasis	0.000136	0.0284	CbGpPWpGaD
Olmesartan—AGTR1—Allograft Rejection—IL17A—psoriasis	0.000125	0.0262	CbGpPWpGaD
Olmesartan—Feeling abnormal—Cyclosporine—psoriasis	0.000124	0.000433	CcSEcCtD
Olmesartan—Shock—Triamcinolone—psoriasis	0.000124	0.000432	CcSEcCtD
Olmesartan—Insomnia—Prednisolone—psoriasis	0.000124	0.000432	CcSEcCtD
Olmesartan—Alopecia—Prednisone—psoriasis	0.000124	0.000432	CcSEcCtD
Olmesartan—Gastrointestinal pain—Cyclosporine—psoriasis	0.000123	0.000429	CcSEcCtD
Olmesartan—Loss of consciousness—Betamethasone—psoriasis	0.000123	0.000429	CcSEcCtD
Olmesartan—Loss of consciousness—Dexamethasone—psoriasis	0.000123	0.000429	CcSEcCtD
Olmesartan—Dizziness—Mycophenolic acid—psoriasis	0.000123	0.000429	CcSEcCtD
Olmesartan—Tachycardia—Triamcinolone—psoriasis	0.000123	0.000429	CcSEcCtD
Olmesartan—Mental disorder—Prednisone—psoriasis	0.000123	0.000428	CcSEcCtD
Olmesartan—Malnutrition—Prednisone—psoriasis	0.000122	0.000425	CcSEcCtD
Olmesartan—Musculoskeletal discomfort—Hydrocortisone—psoriasis	0.000122	0.000425	CcSEcCtD
Olmesartan—Hyperhidrosis—Triamcinolone—psoriasis	0.000122	0.000425	CcSEcCtD
Olmesartan—Agranulocytosis—Methotrexate—psoriasis	0.000122	0.000425	CcSEcCtD
Olmesartan—Feeling abnormal—Mycophenolate mofetil—psoriasis	0.000121	0.000422	CcSEcCtD
Olmesartan—Insomnia—Hydrocortisone—psoriasis	0.000121	0.000422	CcSEcCtD
Olmesartan—Gastrointestinal pain—Mycophenolate mofetil—psoriasis	0.00012	0.000419	CcSEcCtD
Olmesartan—Urticaria—Cyclosporine—psoriasis	0.00012	0.000417	CcSEcCtD
Olmesartan—Myalgia—Betamethasone—psoriasis	0.00012	0.000416	CcSEcCtD
Olmesartan—Myalgia—Dexamethasone—psoriasis	0.00012	0.000416	CcSEcCtD
Olmesartan—Abdominal pain—Cyclosporine—psoriasis	0.000119	0.000415	CcSEcCtD
Olmesartan—Body temperature increased—Cyclosporine—psoriasis	0.000119	0.000415	CcSEcCtD
Olmesartan—Anxiety—Dexamethasone—psoriasis	0.000119	0.000415	CcSEcCtD
Olmesartan—Anxiety—Betamethasone—psoriasis	0.000119	0.000415	CcSEcCtD
Olmesartan—Vomiting—Mycophenolic acid—psoriasis	0.000119	0.000413	CcSEcCtD
Olmesartan—Discomfort—Dexamethasone—psoriasis	0.000118	0.000411	CcSEcCtD
Olmesartan—Discomfort—Betamethasone—psoriasis	0.000118	0.000411	CcSEcCtD
Olmesartan—Dyspepsia—Hydrocortisone—psoriasis	0.000118	0.000411	CcSEcCtD
Olmesartan—Rash—Mycophenolic acid—psoriasis	0.000118	0.000409	CcSEcCtD
Olmesartan—Dermatitis—Mycophenolic acid—psoriasis	0.000118	0.000409	CcSEcCtD
Olmesartan—Pain—Prednisolone—psoriasis	0.000118	0.000409	CcSEcCtD
Olmesartan—Urticaria—Mycophenolate mofetil—psoriasis	0.000117	0.000407	CcSEcCtD
Olmesartan—Headache—Mycophenolic acid—psoriasis	0.000117	0.000407	CcSEcCtD
Olmesartan—Decreased appetite—Hydrocortisone—psoriasis	0.000117	0.000406	CcSEcCtD
Olmesartan—Pharyngitis—Methotrexate—psoriasis	0.000117	0.000405	CcSEcCtD
Olmesartan—Body temperature increased—Mycophenolate mofetil—psoriasis	0.000116	0.000405	CcSEcCtD
Olmesartan—Abdominal pain—Mycophenolate mofetil—psoriasis	0.000116	0.000405	CcSEcCtD
Olmesartan—AGTR1—Allograft Rejection—IL12B—psoriasis	0.000116	0.0243	CbGpPWpGaD
Olmesartan—Urinary tract disorder—Methotrexate—psoriasis	0.000116	0.000403	CcSEcCtD
Olmesartan—Gastrointestinal disorder—Hydrocortisone—psoriasis	0.000116	0.000403	CcSEcCtD
Olmesartan—Fatigue—Hydrocortisone—psoriasis	0.000116	0.000402	CcSEcCtD
Olmesartan—Vision blurred—Prednisone—psoriasis	0.000115	0.000401	CcSEcCtD
Olmesartan—Urethral disorder—Methotrexate—psoriasis	0.000115	0.0004	CcSEcCtD
Olmesartan—Musculoskeletal discomfort—Triamcinolone—psoriasis	0.000115	0.0004	CcSEcCtD
Olmesartan—Pain—Hydrocortisone—psoriasis	0.000115	0.000399	CcSEcCtD
Olmesartan—Oedema—Dexamethasone—psoriasis	0.000115	0.000399	CcSEcCtD
Olmesartan—Anaphylactic shock—Betamethasone—psoriasis	0.000115	0.000399	CcSEcCtD
Olmesartan—Oedema—Betamethasone—psoriasis	0.000115	0.000399	CcSEcCtD
Olmesartan—Anaphylactic shock—Dexamethasone—psoriasis	0.000115	0.000399	CcSEcCtD
Olmesartan—Insomnia—Triamcinolone—psoriasis	0.000114	0.000397	CcSEcCtD
Olmesartan—Infection—Dexamethasone—psoriasis	0.000114	0.000396	CcSEcCtD
Olmesartan—Infection—Betamethasone—psoriasis	0.000114	0.000396	CcSEcCtD
Olmesartan—Ill-defined disorder—Prednisone—psoriasis	0.000114	0.000395	CcSEcCtD
Olmesartan—AGTR1—Allograft Rejection—HLA-E—psoriasis	0.000113	0.0238	CbGpPWpGaD
Olmesartan—Feeling abnormal—Prednisolone—psoriasis	0.000113	0.000394	CcSEcCtD
Olmesartan—Anaemia—Prednisone—psoriasis	0.000113	0.000393	CcSEcCtD
Olmesartan—Shock—Betamethasone—psoriasis	0.000113	0.000392	CcSEcCtD
Olmesartan—Shock—Dexamethasone—psoriasis	0.000113	0.000392	CcSEcCtD
Olmesartan—Nervous system disorder—Dexamethasone—psoriasis	0.000112	0.000391	CcSEcCtD
Olmesartan—Nervous system disorder—Betamethasone—psoriasis	0.000112	0.000391	CcSEcCtD
Olmesartan—Agitation—Prednisone—psoriasis	0.000112	0.000391	CcSEcCtD
Olmesartan—Thrombocytopenia—Dexamethasone—psoriasis	0.000112	0.00039	CcSEcCtD
Olmesartan—Thrombocytopenia—Betamethasone—psoriasis	0.000112	0.00039	CcSEcCtD
Olmesartan—Tachycardia—Dexamethasone—psoriasis	0.000112	0.000389	CcSEcCtD
Olmesartan—Tachycardia—Betamethasone—psoriasis	0.000112	0.000389	CcSEcCtD
Olmesartan—Angioedema—Prednisone—psoriasis	0.000112	0.000389	CcSEcCtD
Olmesartan—Dyspepsia—Triamcinolone—psoriasis	0.000111	0.000387	CcSEcCtD
Olmesartan—Nausea—Mycophenolic acid—psoriasis	0.000111	0.000386	CcSEcCtD
Olmesartan—Hyperhidrosis—Dexamethasone—psoriasis	0.000111	0.000385	CcSEcCtD
Olmesartan—Hyperhidrosis—Betamethasone—psoriasis	0.000111	0.000385	CcSEcCtD
Olmesartan—Feeling abnormal—Hydrocortisone—psoriasis	0.000111	0.000385	CcSEcCtD
Olmesartan—Malaise—Prednisone—psoriasis	0.00011	0.000384	CcSEcCtD
Olmesartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	0.00011	0.0231	CbGpPWpGaD
Olmesartan—Vertigo—Prednisone—psoriasis	0.00011	0.000382	CcSEcCtD
Olmesartan—Gastrointestinal pain—Hydrocortisone—psoriasis	0.00011	0.000382	CcSEcCtD
Olmesartan—Syncope—Prednisone—psoriasis	0.00011	0.000382	CcSEcCtD
Olmesartan—Anorexia—Dexamethasone—psoriasis	0.000109	0.00038	CcSEcCtD
Olmesartan—Anorexia—Betamethasone—psoriasis	0.000109	0.00038	CcSEcCtD
Olmesartan—Urticaria—Prednisolone—psoriasis	0.000109	0.00038	CcSEcCtD
Olmesartan—Fatigue—Triamcinolone—psoriasis	0.000109	0.000379	CcSEcCtD
Olmesartan—Asthenia—Cyclosporine—psoriasis	0.000108	0.000377	CcSEcCtD
Olmesartan—Pain—Triamcinolone—psoriasis	0.000108	0.000376	CcSEcCtD
Olmesartan—Loss of consciousness—Prednisone—psoriasis	0.000108	0.000374	CcSEcCtD
Olmesartan—Hypotension—Dexamethasone—psoriasis	0.000107	0.000373	CcSEcCtD
Olmesartan—Hypotension—Betamethasone—psoriasis	0.000107	0.000373	CcSEcCtD
Olmesartan—ABCC2—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000107	0.0224	CbGpPWpGaD
Olmesartan—Pruritus—Cyclosporine—psoriasis	0.000107	0.000372	CcSEcCtD
Olmesartan—Urticaria—Hydrocortisone—psoriasis	0.000107	0.000371	CcSEcCtD
Olmesartan—Angiopathy—Methotrexate—psoriasis	0.000107	0.000371	CcSEcCtD
Olmesartan—Abdominal pain—Hydrocortisone—psoriasis	0.000106	0.000369	CcSEcCtD
Olmesartan—Body temperature increased—Hydrocortisone—psoriasis	0.000106	0.000369	CcSEcCtD
Olmesartan—Mediastinal disorder—Methotrexate—psoriasis	0.000106	0.000368	CcSEcCtD
Olmesartan—Asthenia—Mycophenolate mofetil—psoriasis	0.000106	0.000368	CcSEcCtD
Olmesartan—Musculoskeletal discomfort—Dexamethasone—psoriasis	0.000104	0.000363	CcSEcCtD
Olmesartan—Musculoskeletal discomfort—Betamethasone—psoriasis	0.000104	0.000363	CcSEcCtD
Olmesartan—Pruritus—Mycophenolate mofetil—psoriasis	0.000104	0.000362	CcSEcCtD
Olmesartan—Arthralgia—Prednisone—psoriasis	0.000104	0.000362	CcSEcCtD
Olmesartan—Myalgia—Prednisone—psoriasis	0.000104	0.000362	CcSEcCtD
Olmesartan—Feeling abnormal—Triamcinolone—psoriasis	0.000104	0.000362	CcSEcCtD
Olmesartan—Anxiety—Prednisone—psoriasis	0.000104	0.000361	CcSEcCtD
Olmesartan—Alopecia—Methotrexate—psoriasis	0.000104	0.000361	CcSEcCtD
Olmesartan—Insomnia—Dexamethasone—psoriasis	0.000104	0.000361	CcSEcCtD
Olmesartan—Insomnia—Betamethasone—psoriasis	0.000104	0.000361	CcSEcCtD
Olmesartan—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	0.000103	0.00036	CcSEcCtD
Olmesartan—Diarrhoea—Cyclosporine—psoriasis	0.000103	0.000359	CcSEcCtD
Olmesartan—Discomfort—Prednisone—psoriasis	0.000103	0.000358	CcSEcCtD
Olmesartan—Mental disorder—Methotrexate—psoriasis	0.000103	0.000358	CcSEcCtD
Olmesartan—Malnutrition—Methotrexate—psoriasis	0.000102	0.000356	CcSEcCtD
Olmesartan—Dyspepsia—Betamethasone—psoriasis	0.000101	0.000351	CcSEcCtD
Olmesartan—Dyspepsia—Dexamethasone—psoriasis	0.000101	0.000351	CcSEcCtD
Olmesartan—Diarrhoea—Mycophenolate mofetil—psoriasis	0.000101	0.000351	CcSEcCtD
Olmesartan—Urticaria—Triamcinolone—psoriasis	0.0001	0.000349	CcSEcCtD
Olmesartan—Body temperature increased—Triamcinolone—psoriasis	9.99e-05	0.000347	CcSEcCtD
Olmesartan—Dizziness—Cyclosporine—psoriasis	9.99e-05	0.000347	CcSEcCtD
Olmesartan—Anaphylactic shock—Prednisone—psoriasis	9.99e-05	0.000347	CcSEcCtD
Olmesartan—Oedema—Prednisone—psoriasis	9.99e-05	0.000347	CcSEcCtD
Olmesartan—Decreased appetite—Betamethasone—psoriasis	9.97e-05	0.000347	CcSEcCtD
Olmesartan—Decreased appetite—Dexamethasone—psoriasis	9.97e-05	0.000347	CcSEcCtD
Olmesartan—Infection—Prednisone—psoriasis	9.92e-05	0.000345	CcSEcCtD
Olmesartan—Gastrointestinal disorder—Betamethasone—psoriasis	9.9e-05	0.000344	CcSEcCtD
Olmesartan—Gastrointestinal disorder—Dexamethasone—psoriasis	9.9e-05	0.000344	CcSEcCtD
Olmesartan—Back pain—Methotrexate—psoriasis	9.89e-05	0.000344	CcSEcCtD
Olmesartan—Fatigue—Dexamethasone—psoriasis	9.89e-05	0.000344	CcSEcCtD
Olmesartan—Fatigue—Betamethasone—psoriasis	9.89e-05	0.000344	CcSEcCtD
Olmesartan—Shock—Prednisone—psoriasis	9.82e-05	0.000342	CcSEcCtD
Olmesartan—Pain—Betamethasone—psoriasis	9.81e-05	0.000341	CcSEcCtD
Olmesartan—Pain—Dexamethasone—psoriasis	9.81e-05	0.000341	CcSEcCtD
Olmesartan—Nervous system disorder—Prednisone—psoriasis	9.79e-05	0.000341	CcSEcCtD
Olmesartan—Tachycardia—Prednisone—psoriasis	9.75e-05	0.000339	CcSEcCtD
Olmesartan—Dizziness—Mycophenolate mofetil—psoriasis	9.74e-05	0.000339	CcSEcCtD
Olmesartan—Skin disorder—Prednisone—psoriasis	9.7e-05	0.000337	CcSEcCtD
Olmesartan—Hyperhidrosis—Prednisone—psoriasis	9.65e-05	0.000336	CcSEcCtD
Olmesartan—Vision blurred—Methotrexate—psoriasis	9.64e-05	0.000335	CcSEcCtD
Olmesartan—Asthenia—Hydrocortisone—psoriasis	9.63e-05	0.000335	CcSEcCtD
Olmesartan—Vomiting—Cyclosporine—psoriasis	9.6e-05	0.000334	CcSEcCtD
Olmesartan—Rash—Cyclosporine—psoriasis	9.52e-05	0.000331	CcSEcCtD
Olmesartan—Anorexia—Prednisone—psoriasis	9.52e-05	0.000331	CcSEcCtD
Olmesartan—Dermatitis—Cyclosporine—psoriasis	9.51e-05	0.000331	CcSEcCtD
Olmesartan—Pruritus—Hydrocortisone—psoriasis	9.5e-05	0.00033	CcSEcCtD
Olmesartan—Ill-defined disorder—Methotrexate—psoriasis	9.49e-05	0.00033	CcSEcCtD
Olmesartan—Headache—Cyclosporine—psoriasis	9.46e-05	0.000329	CcSEcCtD
Olmesartan—Anaemia—Methotrexate—psoriasis	9.45e-05	0.000329	CcSEcCtD
Olmesartan—Feeling abnormal—Betamethasone—psoriasis	9.45e-05	0.000329	CcSEcCtD
Olmesartan—Feeling abnormal—Dexamethasone—psoriasis	9.45e-05	0.000329	CcSEcCtD
Olmesartan—Gastrointestinal pain—Betamethasone—psoriasis	9.38e-05	0.000326	CcSEcCtD
Olmesartan—Gastrointestinal pain—Dexamethasone—psoriasis	9.38e-05	0.000326	CcSEcCtD
Olmesartan—Vomiting—Mycophenolate mofetil—psoriasis	9.37e-05	0.000326	CcSEcCtD
Olmesartan—Rash—Mycophenolate mofetil—psoriasis	9.29e-05	0.000323	CcSEcCtD
Olmesartan—Dermatitis—Mycophenolate mofetil—psoriasis	9.28e-05	0.000323	CcSEcCtD
Olmesartan—Headache—Mycophenolate mofetil—psoriasis	9.23e-05	0.000321	CcSEcCtD
Olmesartan—Malaise—Methotrexate—psoriasis	9.22e-05	0.000321	CcSEcCtD
Olmesartan—Vertigo—Methotrexate—psoriasis	9.19e-05	0.000319	CcSEcCtD
Olmesartan—Diarrhoea—Hydrocortisone—psoriasis	9.18e-05	0.000319	CcSEcCtD
Olmesartan—Leukopenia—Methotrexate—psoriasis	9.15e-05	0.000318	CcSEcCtD
Olmesartan—Urticaria—Dexamethasone—psoriasis	9.11e-05	0.000317	CcSEcCtD
Olmesartan—Urticaria—Betamethasone—psoriasis	9.11e-05	0.000317	CcSEcCtD
Olmesartan—Musculoskeletal discomfort—Prednisone—psoriasis	9.1e-05	0.000316	CcSEcCtD
Olmesartan—Dizziness—Prednisolone—psoriasis	9.09e-05	0.000316	CcSEcCtD
Olmesartan—Asthenia—Triamcinolone—psoriasis	9.07e-05	0.000315	CcSEcCtD
Olmesartan—Body temperature increased—Betamethasone—psoriasis	9.06e-05	0.000315	CcSEcCtD
Olmesartan—Body temperature increased—Dexamethasone—psoriasis	9.06e-05	0.000315	CcSEcCtD
Olmesartan—Abdominal pain—Dexamethasone—psoriasis	9.06e-05	0.000315	CcSEcCtD
Olmesartan—Abdominal pain—Betamethasone—psoriasis	9.06e-05	0.000315	CcSEcCtD
Olmesartan—Insomnia—Prednisone—psoriasis	9.03e-05	0.000314	CcSEcCtD
Olmesartan—Nausea—Cyclosporine—psoriasis	8.97e-05	0.000312	CcSEcCtD
Olmesartan—Pruritus—Triamcinolone—psoriasis	8.94e-05	0.000311	CcSEcCtD
Olmesartan—Cough—Methotrexate—psoriasis	8.92e-05	0.00031	CcSEcCtD
Olmesartan—Dizziness—Hydrocortisone—psoriasis	8.87e-05	0.000309	CcSEcCtD
Olmesartan—Dyspepsia—Prednisone—psoriasis	8.79e-05	0.000306	CcSEcCtD
Olmesartan—Nausea—Mycophenolate mofetil—psoriasis	8.75e-05	0.000304	CcSEcCtD
Olmesartan—Chest pain—Methotrexate—psoriasis	8.71e-05	0.000303	CcSEcCtD
Olmesartan—Arthralgia—Methotrexate—psoriasis	8.71e-05	0.000303	CcSEcCtD
Olmesartan—Myalgia—Methotrexate—psoriasis	8.71e-05	0.000303	CcSEcCtD
Olmesartan—Decreased appetite—Prednisone—psoriasis	8.68e-05	0.000302	CcSEcCtD
Olmesartan—Rash—Prednisolone—psoriasis	8.66e-05	0.000301	CcSEcCtD
Olmesartan—Dermatitis—Prednisolone—psoriasis	8.66e-05	0.000301	CcSEcCtD
Olmesartan—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	8.65e-05	0.000301	CcSEcCtD
Olmesartan—Fatigue—Prednisone—psoriasis	8.61e-05	0.000299	CcSEcCtD
Olmesartan—Headache—Prednisolone—psoriasis	8.61e-05	0.000299	CcSEcCtD
Olmesartan—Discomfort—Methotrexate—psoriasis	8.6e-05	0.000299	CcSEcCtD
Olmesartan—Constipation—Prednisone—psoriasis	8.54e-05	0.000297	CcSEcCtD
Olmesartan—Vomiting—Hydrocortisone—psoriasis	8.53e-05	0.000297	CcSEcCtD
Olmesartan—AGTR1—Peptide ligand-binding receptors—CCL20—psoriasis	8.52e-05	0.0179	CbGpPWpGaD
Olmesartan—AGTR1—Allograft Rejection—IL10—psoriasis	8.49e-05	0.0178	CbGpPWpGaD
Olmesartan—Rash—Hydrocortisone—psoriasis	8.46e-05	0.000294	CcSEcCtD
Olmesartan—Dermatitis—Hydrocortisone—psoriasis	8.45e-05	0.000294	CcSEcCtD
Olmesartan—Headache—Hydrocortisone—psoriasis	8.41e-05	0.000292	CcSEcCtD
Olmesartan—AGTR1—GPCR ligand binding—HCAR2—psoriasis	8.38e-05	0.0176	CbGpPWpGaD
Olmesartan—Dizziness—Triamcinolone—psoriasis	8.36e-05	0.000291	CcSEcCtD
Olmesartan—Anaphylactic shock—Methotrexate—psoriasis	8.35e-05	0.00029	CcSEcCtD
Olmesartan—Infection—Methotrexate—psoriasis	8.29e-05	0.000288	CcSEcCtD
Olmesartan—AGTR1—Allograft Rejection—IL4—psoriasis	8.26e-05	0.0173	CbGpPWpGaD
Olmesartan—Feeling abnormal—Prednisone—psoriasis	8.23e-05	0.000286	CcSEcCtD
Olmesartan—Asthenia—Betamethasone—psoriasis	8.23e-05	0.000286	CcSEcCtD
Olmesartan—Asthenia—Dexamethasone—psoriasis	8.23e-05	0.000286	CcSEcCtD
Olmesartan—Nervous system disorder—Methotrexate—psoriasis	8.18e-05	0.000285	CcSEcCtD
Olmesartan—Thrombocytopenia—Methotrexate—psoriasis	8.17e-05	0.000284	CcSEcCtD
Olmesartan—Gastrointestinal pain—Prednisone—psoriasis	8.17e-05	0.000284	CcSEcCtD
Olmesartan—Nausea—Prednisolone—psoriasis	8.16e-05	0.000284	CcSEcCtD
Olmesartan—Pruritus—Betamethasone—psoriasis	8.11e-05	0.000282	CcSEcCtD
Olmesartan—Pruritus—Dexamethasone—psoriasis	8.11e-05	0.000282	CcSEcCtD
Olmesartan—Skin disorder—Methotrexate—psoriasis	8.11e-05	0.000282	CcSEcCtD
Olmesartan—AGTR1—Allograft Rejection—HLA-B—psoriasis	8.07e-05	0.0169	CbGpPWpGaD
Olmesartan—Hyperhidrosis—Methotrexate—psoriasis	8.07e-05	0.000281	CcSEcCtD
Olmesartan—Vomiting—Triamcinolone—psoriasis	8.03e-05	0.000279	CcSEcCtD
Olmesartan—Nausea—Hydrocortisone—psoriasis	7.97e-05	0.000277	CcSEcCtD
Olmesartan—Rash—Triamcinolone—psoriasis	7.97e-05	0.000277	CcSEcCtD
Olmesartan—Dermatitis—Triamcinolone—psoriasis	7.96e-05	0.000277	CcSEcCtD
Olmesartan—Anorexia—Methotrexate—psoriasis	7.95e-05	0.000277	CcSEcCtD
Olmesartan—Urticaria—Prednisone—psoriasis	7.93e-05	0.000276	CcSEcCtD
Olmesartan—Headache—Triamcinolone—psoriasis	7.92e-05	0.000275	CcSEcCtD
Olmesartan—Abdominal pain—Prednisone—psoriasis	7.89e-05	0.000275	CcSEcCtD
Olmesartan—Body temperature increased—Prednisone—psoriasis	7.89e-05	0.000275	CcSEcCtD
Olmesartan—Diarrhoea—Betamethasone—psoriasis	7.85e-05	0.000273	CcSEcCtD
Olmesartan—Diarrhoea—Dexamethasone—psoriasis	7.85e-05	0.000273	CcSEcCtD
Olmesartan—Hypotension—Methotrexate—psoriasis	7.8e-05	0.000271	CcSEcCtD
Olmesartan—Musculoskeletal discomfort—Methotrexate—psoriasis	7.6e-05	0.000264	CcSEcCtD
Olmesartan—Dizziness—Dexamethasone—psoriasis	7.58e-05	0.000264	CcSEcCtD
Olmesartan—Dizziness—Betamethasone—psoriasis	7.58e-05	0.000264	CcSEcCtD
Olmesartan—Insomnia—Methotrexate—psoriasis	7.55e-05	0.000262	CcSEcCtD
Olmesartan—Nausea—Triamcinolone—psoriasis	7.51e-05	0.000261	CcSEcCtD
Olmesartan—AGTR1—Allograft Rejection—HLA-A—psoriasis	7.48e-05	0.0157	CbGpPWpGaD
Olmesartan—ABCC2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	7.45e-05	0.0156	CbGpPWpGaD
Olmesartan—Dyspepsia—Methotrexate—psoriasis	7.35e-05	0.000255	CcSEcCtD
Olmesartan—Vomiting—Betamethasone—psoriasis	7.29e-05	0.000254	CcSEcCtD
Olmesartan—Vomiting—Dexamethasone—psoriasis	7.29e-05	0.000254	CcSEcCtD
Olmesartan—Decreased appetite—Methotrexate—psoriasis	7.25e-05	0.000252	CcSEcCtD
Olmesartan—Rash—Dexamethasone—psoriasis	7.23e-05	0.000251	CcSEcCtD
Olmesartan—Rash—Betamethasone—psoriasis	7.23e-05	0.000251	CcSEcCtD
Olmesartan—Dermatitis—Betamethasone—psoriasis	7.22e-05	0.000251	CcSEcCtD
Olmesartan—Dermatitis—Dexamethasone—psoriasis	7.22e-05	0.000251	CcSEcCtD
Olmesartan—Gastrointestinal disorder—Methotrexate—psoriasis	7.2e-05	0.000251	CcSEcCtD
Olmesartan—Fatigue—Methotrexate—psoriasis	7.19e-05	0.00025	CcSEcCtD
Olmesartan—Headache—Dexamethasone—psoriasis	7.18e-05	0.00025	CcSEcCtD
Olmesartan—Headache—Betamethasone—psoriasis	7.18e-05	0.00025	CcSEcCtD
Olmesartan—Asthenia—Prednisone—psoriasis	7.16e-05	0.000249	CcSEcCtD
Olmesartan—Pain—Methotrexate—psoriasis	7.14e-05	0.000248	CcSEcCtD
Olmesartan—Pruritus—Prednisone—psoriasis	7.06e-05	0.000246	CcSEcCtD
Olmesartan—Feeling abnormal—Methotrexate—psoriasis	6.88e-05	0.000239	CcSEcCtD
Olmesartan—AGTR1—Allograft Rejection—HLA-DRB1—psoriasis	6.84e-05	0.0143	CbGpPWpGaD
Olmesartan—Diarrhoea—Prednisone—psoriasis	6.83e-05	0.000238	CcSEcCtD
Olmesartan—Gastrointestinal pain—Methotrexate—psoriasis	6.82e-05	0.000237	CcSEcCtD
Olmesartan—Nausea—Dexamethasone—psoriasis	6.81e-05	0.000237	CcSEcCtD
Olmesartan—Nausea—Betamethasone—psoriasis	6.81e-05	0.000237	CcSEcCtD
Olmesartan—Urticaria—Methotrexate—psoriasis	6.63e-05	0.000231	CcSEcCtD
Olmesartan—Dizziness—Prednisone—psoriasis	6.6e-05	0.00023	CcSEcCtD
Olmesartan—Abdominal pain—Methotrexate—psoriasis	6.6e-05	0.000229	CcSEcCtD
Olmesartan—Body temperature increased—Methotrexate—psoriasis	6.6e-05	0.000229	CcSEcCtD
Olmesartan—Vomiting—Prednisone—psoriasis	6.35e-05	0.000221	CcSEcCtD
Olmesartan—Rash—Prednisone—psoriasis	6.3e-05	0.000219	CcSEcCtD
Olmesartan—Dermatitis—Prednisone—psoriasis	6.29e-05	0.000219	CcSEcCtD
Olmesartan—Headache—Prednisone—psoriasis	6.26e-05	0.000218	CcSEcCtD
Olmesartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—NFKB1—psoriasis	5.99e-05	0.0126	CbGpPWpGaD
Olmesartan—Asthenia—Methotrexate—psoriasis	5.99e-05	0.000208	CcSEcCtD
Olmesartan—Nausea—Prednisone—psoriasis	5.93e-05	0.000206	CcSEcCtD
Olmesartan—Pruritus—Methotrexate—psoriasis	5.9e-05	0.000205	CcSEcCtD
Olmesartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	5.71e-05	0.012	CbGpPWpGaD
Olmesartan—Diarrhoea—Methotrexate—psoriasis	5.71e-05	0.000199	CcSEcCtD
Olmesartan—ABCC2—NRF2 pathway—TGFA—psoriasis	5.58e-05	0.0117	CbGpPWpGaD
Olmesartan—Dizziness—Methotrexate—psoriasis	5.52e-05	0.000192	CcSEcCtD
Olmesartan—Vomiting—Methotrexate—psoriasis	5.31e-05	0.000185	CcSEcCtD
Olmesartan—Rash—Methotrexate—psoriasis	5.26e-05	0.000183	CcSEcCtD
Olmesartan—Dermatitis—Methotrexate—psoriasis	5.26e-05	0.000183	CcSEcCtD
Olmesartan—Headache—Methotrexate—psoriasis	5.23e-05	0.000182	CcSEcCtD
Olmesartan—SLCO1B3—SLC-mediated transmembrane transport—CP—psoriasis	5.15e-05	0.0108	CbGpPWpGaD
Olmesartan—AGTR1—Allograft Rejection—IFNG—psoriasis	4.99e-05	0.0105	CbGpPWpGaD
Olmesartan—Nausea—Methotrexate—psoriasis	4.96e-05	0.000172	CcSEcCtD
Olmesartan—AGTR1—GPCR downstream signaling—HCAR2—psoriasis	4.73e-05	0.00992	CbGpPWpGaD
Olmesartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—TNF—psoriasis	4.66e-05	0.00977	CbGpPWpGaD
Olmesartan—AGTR1—Allograft Rejection—CXCL8—psoriasis	4.64e-05	0.00973	CbGpPWpGaD
Olmesartan—AGTR1—GPCR ligand binding—CCL20—psoriasis	4.35e-05	0.00912	CbGpPWpGaD
Olmesartan—AGTR1—Signaling by GPCR—HCAR2—psoriasis	4.3e-05	0.00901	CbGpPWpGaD
Olmesartan—AGTR1—Allograft Rejection—VEGFA—psoriasis	3.77e-05	0.0079	CbGpPWpGaD
Olmesartan—SLCO1B1—SLC-mediated transmembrane transport—CP—psoriasis	3.46e-05	0.00726	CbGpPWpGaD
Olmesartan—AGTR1—Allograft Rejection—TNF—psoriasis	3.23e-05	0.00677	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—NDUFA5—psoriasis	2.82e-05	0.00591	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2.63e-05	0.00551	CbGpPWpGaD
Olmesartan—SLCO1B3—Transmembrane transport of small molecules—CP—psoriasis	2.62e-05	0.00549	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—HCAR2—psoriasis	2.54e-05	0.00532	CbGpPWpGaD
Olmesartan—SLCO1B3—Transmembrane transport of small molecules—CARM1—psoriasis	2.5e-05	0.00524	CbGpPWpGaD
Olmesartan—AGTR1—GPCR downstream signaling—CCL20—psoriasis	2.46e-05	0.00515	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—CYP2S1—psoriasis	2.4e-05	0.00502	CbGpPWpGaD
Olmesartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—TYK2—psoriasis	2.39e-05	0.00502	CbGpPWpGaD
Olmesartan—AGTR1—Peptide ligand-binding receptors—CXCL8—psoriasis	2.3e-05	0.00482	CbGpPWpGaD
Olmesartan—AGTR1—Signaling by GPCR—CCL20—psoriasis	2.23e-05	0.00468	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—TAGAP—psoriasis	2.2e-05	0.00462	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—NDUFA5—psoriasis	1.89e-05	0.00397	CbGpPWpGaD
Olmesartan—ABCC2—Transmembrane transport of small molecules—CP—psoriasis	1.87e-05	0.00393	CbGpPWpGaD
Olmesartan—ABCC2—Transmembrane transport of small molecules—CARM1—psoriasis	1.79e-05	0.00375	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism of lipids and lipoproteins—CARM1—psoriasis	1.77e-05	0.0037	CbGpPWpGaD
Olmesartan—SLCO1B1—Transmembrane transport of small molecules—CP—psoriasis	1.76e-05	0.00369	CbGpPWpGaD
Olmesartan—SLCO1B1—Transmembrane transport of small molecules—CARM1—psoriasis	1.68e-05	0.00352	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—CYP2S1—psoriasis	1.61e-05	0.00338	CbGpPWpGaD
Olmesartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	1.54e-05	0.00323	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—CCL20—psoriasis	1.32e-05	0.00277	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.26e-05	0.00263	CbGpPWpGaD
Olmesartan—AGTR1—GPCR ligand binding—CXCL8—psoriasis	1.17e-05	0.00246	CbGpPWpGaD
Olmesartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—psoriasis	1.17e-05	0.00245	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—CARM1—psoriasis	1.17e-05	0.00245	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.09e-05	0.00229	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism of lipids and lipoproteins—APOE—psoriasis	8.44e-06	0.00177	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—CARM1—psoriasis	7.86e-06	0.00165	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism of lipids and lipoproteins—PPARG—psoriasis	7.35e-06	0.00154	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—SOCS1—psoriasis	7.26e-06	0.00152	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—CAT—psoriasis	7.2e-06	0.00151	CbGpPWpGaD
Olmesartan—AGTR1—Signaling by GPCR—TYK2—psoriasis	6.93e-06	0.00145	CbGpPWpGaD
Olmesartan—AGTR1—GPCR downstream signaling—CXCL8—psoriasis	6.64e-06	0.00139	CbGpPWpGaD
Olmesartan—AGTR1—Signaling by GPCR—CXCL8—psoriasis	6.03e-06	0.00126	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—APOE—psoriasis	5.59e-06	0.00117	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—APOE—psoriasis	5.36e-06	0.00112	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—LEP—psoriasis	5.36e-06	0.00112	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—NFKBIA—psoriasis	4.99e-06	0.00105	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—PPARG—psoriasis	4.87e-06	0.00102	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—CAT—psoriasis	4.84e-06	0.00101	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—TYK2—psoriasis	4.09e-06	0.000858	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—APOE—psoriasis	3.76e-06	0.000788	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—CXCL8—psoriasis	3.56e-06	0.000747	CbGpPWpGaD
Olmesartan—AGTR1—Signaling by GPCR—IL6—psoriasis	3.39e-06	0.00071	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—JUN—psoriasis	3.31e-06	0.000694	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—PPARG—psoriasis	3.27e-06	0.000686	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—NFKB1—psoriasis	3.19e-06	0.000668	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—VEGFA—psoriasis	2.89e-06	0.000606	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—STAT3—psoriasis	2.86e-06	0.0006	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—TP53—psoriasis	2.19e-06	0.000458	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—IL6—psoriasis	2e-06	0.000419	CbGpPWpGaD
